Housey novel hormonal target program

Housey novel hormonal target program is a preclinical-stage drug discovery program developed by Housey Pharmaceutical Research Laboratories. The program is directed at a novel, undisclosed hormonal target for the treatment of obesity, non-alcoholic steatohepatitis (NASH), and hepatic steatosis. Utilizing Housey's proprietary cell-based functional assay technology, the research aims to identify small molecule modulators that can address metabolic imbalances and lipid accumulation in the liver. The specific mechanism of action involves the regulation of hormonal signaling pathways critical to energy homeostasis and lipid metabolism. By targeting this novel pathway, the therapy seeks to provide a new approach to managing the complex metabolic dysfunction associated with fatty liver disease and excessive body weight.

Other names

Novel Hormonal Target programHousey Obesity/NASH/Steatosis program